Novo Nordisk Shares Plunge on Insulin's FDA Failure
Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."
Most Recent Videos
"Preserving Bombardier C-Series Key Amid 7,500 Job Cuts"
41:03 - Bombardier has announced it will slash 7,500 jobs during a second round of job cuts within the past 8 months. Bloomberg Intelligence Analyst George Ferguson explains whether these cost saving measures were necessary as the struggling aircraft maker awaits $1 billion in federal aid from the Canadian government on Bloomberg TV Canada's The Daily Brief. (Source: Bloomberg)